SOLICITATION NOTICE
Q -- Whole Human Genome Sequencing
- Notice Date
- 5/3/2012
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HG)-2012-139-DLM
- Archive Date
- 5/22/2012
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352, James Richards,
- E-Mail Address
-
maxwelld@mail.nih.gov, richardsje2@mail.nih.gov
(maxwelld@mail.nih.gov, richardsje2@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI), COAC Services Branch, Office of Acquisition (OA), National Institutes of Health (NIH) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Illumina Inc., 9885 Towne Centre Drive, San Diego, California 92121-1975 to procure services for whole genome sequencing (human): 1. Whole Genome Sequencing (Human), 30X Coverage from short-insert paired end reads, Catalog Number: FT-700-2030, Samples: Six (6); and 2. Whole Genome Sequencing (Human), 100-120Gb data generated, from short-insert paired end reads, Catalog Number: FT-701-2030, Samples: Six (6). The sole source determination is based on the fact that National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency conducting and supporting medical discoveries that improve people's health and save lives. The National Human Genome Research Institute (NHGRI), Undiagnosed Diseases Program (UDP) is a trans-National Institute of Health (NIH) initiative that focuses on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, MD. The program was organized by the National Human Genome Research Institute (NHGRI), the NIH Office of Rare Diseases Research (ORDR) and the NIH Clinical Center. Many medical specialties from other NIH research centers and institutes contribute the expertise needed to conduct the program, including endocrinology, immunology, oncology, dermatology, dentistry, cardiology and genetics, among the dozens of participating senior attending physicians. UDP clinical researchers are using advances in DNA sequencing to detect defects in genes that point to known disorders. These tools offer the potential for discoveries about the role of molecular and biochemical events that can cause disease and, eventually, the development of diagnostic and therapeutic approaches for rare and common diseases. Medical condition that eludes diagnosis by a referring physician can be considered undiagnosed and may be of interest to this clinical research program. Of the total number of cases that are referred to this program, a very limited number will be invited to proceed in the study following careful application review by the program's medical team. In general, it takes 8 to 12 weeks for the UDP to evaluate an application, and the waiting list for admission is 2 to 6 months. The Contractor will provide Whole Genome Sequencing (Human), 30X Coverage, from short-insert paired end reads. This package includes consensus sequence from ELAND alignment and called SNPs. This is built using short insert paired end reads only, with at least 30X average sequence coverage. One library will be created per each genome sampled. The delivered dataset will include all reads and quality scores for further downstream analysis. A minimum of 5ug input DNA is needed to perform this service. The Contractor (Illumina Genome Network) links researchers interested in conducting large whole human genome sequencing projects with leading institutes worldwide that provide highly economical and rapid turnaround access to Illumina sequencing. Consisting of CSPro-certified organizations with proven expertise in generating high-quality, economical human genome data, the Illumina Genome Network enables researchers to complete their genome sequencing projects rapidly and confidently. Key Illumina Genome Network differentiators 1. Full service (from sample prep to simplified data analysis) is provided by Illumina or one of its Network Partners: a. Extensive NGS expertise (CSPro-certified, published, owns 10+ ILMN systems for production-level sequencing capacity); b. Data Analysis is performed using CASAVA 1.8 (consensus sequence from ELAND alignment, called SNPs and indels); c. Concordance with whole-genome genotyping arrays (genotype concordance of 99.5% for non-cancer samples); d. Higher coverage offerings (from 30x to 200x); and e. Data Quality: >80% of all reads passing filter have a Q value of Q30 or greater. 2. Illumina Genome Network receives ongoing Informatics and Services improvements from Illumina, which are cycled into our services groups when upgrades are proven to be technically and commercially feasible a. By way of example, the Services group has continually upgraded CASAVA and has replaced the Omni1.0 with the Omni2.5 (orthogonal validation). Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology and the Business Size Standard is 500 Employees. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001) and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-58 April 18, 2012). This requirement is under the SAT of $150,000.00. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by May 7, 2012, 7:30 a.m. Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Inquires to this announcement, referencing synopsis number NHLBI-CSB-(HG)-2012-139-DLM, may be submitted to the National Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. Note: In order to receive an award from NHLBI, contractors must have a valid registration in the Central Contractor Registration (CCR) www.ccr.gov, and ORCA https://orca.bpn.gov/login.aspx.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HG)-2012-139-DLM/listing.html)
- Place of Performance
- Address: National Institutes of Health, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02739023-W 20120505/120504001310-817b44bf2b6cc728a7cb74f8b5b2d3fd (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |